Nightstar Therapeutics plc (NITE) Tops Q3 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to Nightstar Therapeutics plc (NITE) Tops Q3 EPS by 13c

Nightstar Therapeutics (NITE) PT Lowered to $22 at Mizuho Securities

November 14, 2018 8:54 AM EST

Mizuho Securities analyst Difei Yang lowered the price target on Nightstar Therapeutics (NASDAQ: NITE) to $22.00 (from $24.00) while maintaining a Buy rating.

Yang commented, "Nightstar reported earnings yesterday. 3Q18 EPS of $(0.27) came in above FactSet consensus of $(0.39). Nightstar is initiating the Phase 2/3... More

Nightstar Therapeutics plc (NITE) to Commence Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP

November 13, 2018 5:55 AM EST

Nightstar Therapeutics plc (NASDAQ: NITE) today provided an update on recent achievements and upcoming clinical milestones and reported financial results for the quarter ended September 30, 2018.

We are pleased with the upcoming initiation of the Phase 2/3 expansion study in line with our previous guidance after being the first sponsor to establish proof-of-concept in X-linked retinitis pigmentosa, said Dave Fellows, Chief Executive Officer. The modified Phase 2/3 expansion study is designed to be consistent with recommendations in FDAs draft guidance on the development of gene therapy products for retinal disorders, which we believe will allow us to... More